Abstract
Why differentiate low molecular weight heparins for venous thromboembolism?
Highlights
The low molecular weight heparins (LMWHs) represent a group of antithrombotic and anticoagulant drugs which were initially developed for the prophylaxis of surgical thrombosis some 20 years ago
It is clear that the clinical spectrum of the LMWHs is relatively broader from the different anticoagulant/antithrombotic drugs
It is important to differentiate the therapeutic effects of individual LMWH as each of these products is approved for specific indications
Summary
The low molecular weight heparins (LMWHs) represent a group of antithrombotic and anticoagulant drugs which were initially developed for the prophylaxis of surgical thrombosis some 20 years ago. 2. Differentiation of commercially available low molecular weight heparins, which are produced by different methods. 3. Differentiation of the branded low molecular weight heparins from the generic versions of these drugs.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
